Human cytomegalovirus (HCMV) is a potential cofactor in HIV-1 infection. To investigate the mechanism whereby HCMV promotes HIV-1 replication, a PBMC coculture assay which measures HIV-1 p24 antigen release was used as an index ofviral replication. HCMV-stimulated PBMC were capable of inducing HIV-1 replication in cocultures with acutely infected PBMC; however, this occurred only when the PBMC were from HCMV-seropositive donors (598±207 versus 27±10 pg/ml p24 antigen with PBMC from HCMV-seronegative donors on day 6 of coculture). Upon stimulation with HCMV, PBMC obtained exclusively from HCMV-seropositive donors released tumor necrosis factor (TNF)-a (270±79 pg/ml at 18 h of culture). Monoclonal antibodies to TNF-a blocked the activity of HCMV-stimulated PBMC in cocultures both with acutely HIV-1-infected PBMC and with the chronically infected promonocytic line U1. Also, treatment of HCMV-stimulated PBMC with pentoxifylline, an inhibitor of TNF-a mRNA, markedly reduced HIV-1 replication in cocultures both with acutely and chronically infected cells. These results indicate that TNF-a is a key mediator of HIV-1 replication induced by HCMV-stimulated PBMC and support the concept that this cytokine plays an important role in the pathogenesis of HIV-1 infection. (J. Clin. Invest. 1992. 89:574-580.)
Introduction
One of the notable features of HIV-l infection is its prolonged incubation period during which the virus is harbored in a quiescent state in CD4 lymphocytes and mononuclear phagocytes. Soon after recognition of the etiologic role of HIV-1 in AIDS, investigators began to search for cofactors, i.e., agents that could accelerate progression by upregulating expression of HIV-I in chronically infected cells (1) . Human Receivedfor publication 31 May 1991 and in revisedform 12 September 1991.
1. Abbreviations used in this paper: HCMV, human cytomegalovirus; TCID50, 50% tissue culture infectious dose; TNF, tumor necrosis factor; VZV, varicella zoster virus.
AIDS patients (24) , has been proposed to act as such a cofactor. Although there are contradictory reports (5, 6) , coinfection with HCMV has been found by some investigators to adversely influence the course of HIV-I -related disease (7) (8) (9) .
Support for HCMV as a cofactor has been provided by in vitro studies demonstrating increased HIV-l replication or cytopathogenicity in certain T lymphocyte lines upon stimulation with HCMV (10) (11) (12) . Also, HCMV has been shown to stimulate HIV-l replication in PBMC cultures from HIV-l-infected donors (13) . The mechanism underlying these HCMVmediated effects has not been established; however, cytokines that promote HIV-1 expression have been considered to play an important role (1 1). In the present study, we used a PBMC coculture assay to investigate the mechanism whereby HCMV stimulates HIV-1 replication. We hypothesized that upon stimulation with HCMV, PBMC would yield a cytokine that serves as a mediator of HIV-1 replication. Our findings point to a key role of tumor necrosis factor (TNF)-a in this phenomenon. 
Viral isolates and HIV-i-infected cells. The laboratory-adapted
HCMV strain AD169 (American Type Culture Collection, Rockville, MD) was grown in human foreskin fibroblasts (University of Minnesota strain D) and stored in aliquots in liquid nitrogen. The 50% tissue culture infectious dose (TCID50) was determined for the HCMV stock (10-6.5 endpoint) before experimental testing, and concentrations of 10-2.5, 10-3-5, and 10-4-5 TCID50 were used to stimulate PBMC. Varicella zoster virus (VZV) strain Oka (American Type Culture Collection) was also grown in human foreskin fibroblasts, and after determin-by latex agglutination assay, and for VZV by ELISA. All donors were HIV-l seronegative. HCMV reciprocal antibody titers < 4 were classified as negative, and antibody titers 2 4 were considered positive. HCMV antibody titers = 4 were confirmed to be positive by ELISA. PBMC were added to wells of 24-well culture plates (1 X 1O6 cells/well) containing 2 ml of culture medium that consisted of RPMI 1640 (Gibco Laboratories, Grand Island, NY), 2 mM glutamine, 10% heatinactivated pooled human AB serum (Pel-Freeze Biologicals, Rogers, AZ), 200 U/ml of penicillin, and 200 Ag/ml of streptomycin. The pooled human AB serum used in the culture medium had a HCMV titer of 64. The culture medium used in this study contained undectable amounts of endotoxin (< 0.25 U/ml) by Limulus amebocyte lysate assay ( HIV-I antigen assay. HIV-1 antigen levels were measured using an ELISA that detects mainly HIV-l p24 antigen (Abbott Laboratories, North Chicago, IL). A standard curve derived from known amounts of p24 antigen was used to quantity the antigen in coculture supernatants. In each experiment background values, obtained from readings derived from supernatants of wells containing noninfected PBMC, were subtracted from experimental values.
Statistical methods. Where appropriate, data were expressed as mean±SE. For comparison of means of two groups, statistical significance was assessed by Student's t test. Repeated measures analysis of variance was used to evaluate the effects ofantibodies or pentoxifylline using SPSS (SPSS, Inc., Chicago, IL).
Results
HIV-1 replication in cocultures containing acutely infected PBMC. To determine whether HCMV promotes HIV-1 replication in cocultures with acutely infected cells, PBMC from a total of 16 healthy donors were cocultured with HIV-1-infected PBMC. Eight ofthese donors were HCMV seropositive, and eight were HCMV seronegative. Results of experiments from representative donors are shown in Fig. 1 . In the absence of HCMV, cocultures with PBMC from all 16 donors showed little or no evidence of HIV-1 replication after 7 d (p24 antigen levels in supernatants were either undetectable or < 100 pg/ ml). Similarly, when PBMC from the eight HCMV-seronegative donors were treated with HCMV, there was no evidence of HIV-1 replication regardless ofthe HCMV concentration used ( Fig. 1 A) . In contrast, when PBMC from the eight HCMVseropositive donors were treated with HCMV, release ofHIV-1 p24 antigen into coculture supernatants was detected in every case. The amount of p24 antigen, however, varied among the HCMV-seropositive donors and was dependent upon the dose of HCMV used to stimulate the cells (Fig. 1 , B-D). On day 6 of 27±10 pg p24 antigen/ml in cocultures from the eight HCMVseronegative donors (P < 0.01).
To determine whether another herpes group virus could also serve as an activation signal of HIV-1 replication in the PBMC coculture assay system, PBMC from three donors who were both HCMV-and VZV-seropositive were stimulated separately with HCMV (TCID50 I-3 5) or VZV (TCIDI 10-1, 10-2, and l0-3) for 3 d before constituting cocultures with HIV-infected PBMC. On day 4 ofcoculture, p24 antigen was detected in supernatants of cocultures containing PBMC from all three donors when HCMV was used as a stimulus (650±117 pg/ml), whereas the p24 antigen concentration was < 100 pg/ml in supernatants of all cocultures containing VZV-stimulated PBMC. By day 6 ofcoculture, however, HIV-I replication was evident in cocultures containing VZV-stimulated PBMC from each ofthe three donors. With the maximal stimulating dose of VZV (10-2 TCID50), the p24 antigen levels in coculture supernatants were 565±236 pg/ml on day 6 and 992±352 pg/ml on day 7 of coculture; the p24 antigen level was 1538±99 and 1800± 100 pg/ml in the supernatants from cocultures containing HCMV-stimulated PBMC on day 6 18 h, the TNF-a levels in coculture supernatants were still significantly (P < 0.05) elevated at 72 h (56±22 vs. 3±1 pg/ml in the seropositive and seronegative groups, respectively). Levels of IL-13 and IL-6 in supernatants ofHCMV-treated cells were not significantly greater than negative control values at any culture time, and the amounts of all three cytokines released from PBMC that had been stimulated with LPS did not differ at any culture time when cells from the two donor groups were compared (data from the 18 h cultures are shown in Fig. 2 Days of Coculture infected PBMC. In this coculture system, anti-TNF-a antibodies markedly inhibited the activity of HCMV-stimulated PBMC (Fig. 3) . Although there was variability in the capacity of PBMC from individual HCMV-seropositive donors to induce HIV-l replication, as had been documented in initial experiments ( Fig. 1) , the magnitude of the inhibitory effect of anti-TNF-a antibodies was similar with PBMC from each of the three HCMV-seropositive donors tested. When compared with control cocultures containing HCMV-stimulated PBMC that had not been treated with antibodies, the inhibition by anti-TNF-a antibodies (1:1,000) was 81 ±1% on day 7 (F = 28.87, P < 0.001). At a dilution of 1:10,000, anti-TNF-a antibodies were slightly less potent (69±3%, P < 0.01). Control antibodies, at both dilutions, did not block the HIV-1 replication induced by HCMV-stimulated PBMC (Fig. 3) . lated PBMC was reduced by anti-TNF-a antibodies but not by control antibodies (Fig. 4) . When compared with control cocultures containing HCMV-stimulated PBMC that had not been treated with antibodies, the inhibition by 1:1,000 dilution of anti-TNF-a antibodies was 47±4% on day 5 of coculture (F = 33.01, P < 0.01). A somewhat smaller inhibitory effect (40±8%, P < 0.05) was seen with the 1:10,000 dilution of specific antibodies, and control antibodies had no effect on HIV-1 expression in this coculture system (Fig. 4) .
Effect ofpentoxifylline on HIV-J replication. The role of TNF-a as a mediator of HIV-1 replication next was assessed by treating HCMV-stimulated PBMC with pentoxifylline, a known inhibitor of TNF-a biosynthesis (15) (16) (17) (18) . Treatment of HCMV-stimulated PBMC with 100 tg/ml pentoxifylline resulted in a significant reduction of HIV-1 replication when these cells were cocultured with acutely infected PBMC (Fig. 5  A) or with the Ul cell line (Fig. 5 B) (inhibition of 56 and 93%, respectively, when compared with untreated control PBMC).
In cocultures with U 1 cells, significant inhibition was observed at a pentoxifylline concentration as low as 1 gg/ml (Fig. 5 B) .
Discussion
In the present study, we found that TNF-a is a key mediator of HIV-1 replication in cocultures of HCMV-stimulated PBMC B C 3 4 5 Days of Coculture Over the past few years, studies ofin vitro models ofHIV-l infection have provided convincing evidence that TNF-a, a cytokine produced primarily by activated monocytes and lymphocytes, plays an important role in the pathogenesis ofHIV-I (19) . When added to cell cultures, TNF-a has been shown to upregulate HIV-1 expression in chronically infected T-cell (20, 21) and monocytic cell (22) lines and to stimulate viral replication in acutely infected T lymphocytes (23) and monocytederived macrophages (22, 24) . Also, TNF-a has been found to act as a mediator of HIV-1 expression in chronically infected cell lines stimulated with phorbol myristate acetate (25) or with supernatants from LPS-treated macrophages (26) . TNF-a appears to induce HIV-l gene expression in these cell lines by transcriptional mechanisms involving the activation ofnuclear factor-KB (27) .
Although the results of the present study demonstrate that TNF-a plays a major role in the induction ofHIV-1 replication by HCMV-stimulated PBMC, additional mechanisms could also be involved. In addition to TNF-a, IL-6 is known to upregulate the expression of HIV-1 in the U1 clone (22) . Although we could not detect the release ofIL-6 into the supernatants of HCMV-treated PBMC, it is still possible that IL-6, or other stimulatory cytokines (19) , also triggers HIV-1 expression in cocultures with HCMV-stimulated PBMC. The immediate early gene products of HCMV have been shown to be potent transactivators ofHIV-l gene expression (28, 29) which could represent a direct, cytokine-independent mechanism of enhanced HIV-l replication. HCMV recently has been shown to induce receptors for the Fc portion of immunoglobulins on fibroblasts which facilitates HIV-l infection ofthese cells (30) .
If HCMV were to increase Fc receptor expression on monocytes within PBMC cultures, then in the presence ofantibodies to HIV-1, increased monocyte uptake ofHIV-I antibody complexes could represent another cytokine-independent mechanism of enhanced HIV-1 replication by HCMV (30) .
HCMV is known to result in a non-productive or abortive infection when cultured with blood monocytes (31, 32) . The disposition of this virus within the PBMC cultures used in the present study, which are comprised ofmonocytes and lymphocytes, is unknown, as is the precise sequence of events which leads to TNF-a release from these cells. The finding that only PBMC from HCMV-seropositive donors were responsive to HCMV suggests that the process involves cells which recognize or have memory of HCMV antigen. The cell culture medium used in these experiments contained serum with antibodies to HCMV. Whether specific antibodies are required for activation of PBMC from HCMV-seropositive individuals is unknown, and in future studies the influence of anti-HCMV and ofanti-HIV-l antibodies on HIV-1 replication in this coculture system will be explored. Since the genes for TNF-a and IL-lI3 are regulated independently, it is not surprising that HCMV did not elicit the release of IL-lIf. It should be pointed out, however, that other investigators have shown that the interaction of HCMV with PBMC from seronegative donors is associated with the production of an IL-l inhibitor (33, 34) which may play an important role in the immunosuppressive properties of HCMV (35) (36) (37) .
While the demonstration that HCMV can trigger TNF-a release from PBMC is a new finding, this capacity is known to be shared by other viruses (38, 39) . Although initial studies suggested that HIV-1 is also capable of triggering TNF-a release from PBMC (40) , more recent work indicates that this is not the case (41) (42) (43) . Contamination of viral preparations or culture medium with endotoxin could explain some ofthe earlier work with HIV-1, since endotoxin is both ubiquitous and a potent stimulus of TNF-a. In the present study, the findings that HCMV yielded TNF-a and induced HIV-l replication only when PBMC from HCMV-seropositive subjects were used argues against endotoxin being responsible for our findings.
While the biologic function of viral-induced TNF-a is not completely understood, the results ofmost studies indicate that TNF-a is involved in host defense against a wide variety of viruses (44) (45) (46) (47) , including HCMV (47) . HIV-1, on the other hand, takes advantage of this host defense mechanism (19) , and although HIV-1 does not appear to initiate production of TNF-a, opportunistic microorganisms which can do so, such as HCMV, may in the process be serving the purposes of HIV-1. The finding in the present study that another herpes group virus, namely, VZV, can also trigger HIV-l replication in PBMC cocultures indicates that HCMV is not unique in this regard. Although serious VZV infections have been reported in HIV-infected patients (48) , and herpes zoster may herald the development of AIDS (49), nevertheless, HCMV disease is the most common opportunistic viral infection in patients with AIDS and has been recognized as a major source of morbidity and mortality in these patients (2) (3) (4) (5) .
Currently, the mainstay of therapy of HIV-1-infected patients is use of antiviral agents that interfere directly with critical viral enzymes, such as, reverse transcriptase. Another treatment strategy being explored is use of immunomodulators. The observation in the present study that the methylxanthine drug pentoxifylline, which is a known inhibitor of TNF-a mRNA (15) (16) (17) (18) , can block HIV-l replication induced by HCMV-stimulated PBMC is consistent with a recent report by other investigators who studied mitogen-stimulated PBMC (18) . Whether agents which interfere with the production or activity ofTNF-a, such as, pentoxifylline oranti-TNF-a monoclonal antibodies, have any clinical benefit in HIV-1-infected patients awaits the results of carefully controlled clinical trials.
